Evidence map›Paper›PMID 28948714›Full record

ArticleCancer medicine2017

Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials.

Toru Aoyama, Kosuke Kashiwabara, Koji Oba, Michitaka Honda, Sotaro Sadahiro, Chikuma Hamada, Hiromichi Maeda, Shuhei Mayanagi, Mitsuro Kanda, Junichi Sakamoto and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Toru AoyamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.ORCID http://orcid.org/0000-0001-6803-3800
Kosuke KashiwabaraDepartment of Biostatistics, The University of Tokyo, Tokyo, Japan.
Koji ObaDepartment of Biostatistics, The University of Tokyo, Tokyo, Japan.
Michitaka HondaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Sotaro SadahiroDepartment of Surgery, Tokai University, Isehara, Japan.
Chikuma HamadaFaculty of Engineering, Tokyo University of Science, Tokyo, Japan.
Hiromichi MaedaCancer Treatment Center, Kochi Medical School Hospital, Kochi, Japan.
Shuhei MayanagiDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Mitsuro KandaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Junichi SakamotoTokai Central Hospital, Kakamigahara, Japan.
Shigetoyo SajiJapanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan.
Takaki YoshikawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Japanese Foundation for Multidisciplinary Treatment of Cancer · JPThe University of Tokyo · JPFukushima Medical University · JPKanagawa Prefectural Hospital Organization · JPKeio University · JPKochi Medical School Hospital · JPNagoya University · JPTokai University · JPTokyo University of Science · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to determine whether or not the overall survival (OS) and disease-free survival (DFS) were affected by the tumor location in patients who underwent curative resection for colon cancer in a pooled analysis of three large phase III studies performed in Japan. In total, 4029 patients were included in the present study. Patients were classified as having right-side colon cancer (RC) if the primary tumor was located in the cecum, ascending colon, hepatic flexure or transverse colon, and left-side colon cancer (LCC) if the tumor site was within the splenic flexure, descending colon, sigmoid colon or recto sigmoid junction. The risk factors for the OS and DFS were analyzed. In the present study, 1449 patients were RC, and 2580 were LCC. The OS rates at 3 and 5 years after surgery were 87.6% and 81.6% in the RC group and 91.5% and 84.5% in the LCC group, respectively. Uni- and multivariate analyses showed that RRC increased the risk of death by 19.7% (adjusted hazard ratio = 1.197; 95% confidence interval, 1.020-1.408; P = 0.0272). In contrast, the DFS was similar between the two locations. The present study confirmed that the tumor location was a risk factor for the OS in patients who underwent curative treatment for colon cancer. Tumor location may, therefore, need to be considered a stratification factor in future phase III trials of colon cancer.

Indexed as

AdultAgedCecumClinical Trials, Phase III as TopicColonColon, AscendingColon, DescendingColonic NeoplasmsColon, SigmoidColon, TransverseDisease-Free SurvivalFemaleFollow-Up StudiesHumansMaleMiddle AgedColorectal cancerleft side colon cancerrecurrenceright side colon cancersurvival

Identifiers

PMID28948714
PMCPMC5673952
OpenAlexW2759190799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.